Ep41: Bob Langer

Episode Summary

Executive Summary: Bob Langer traces his path from a middle-class Albany childhood and early tinkering to becoming MIT’s most prolific biotech engineer, emphasizing that curiosity, stubbornness, and a focus on high-impact problems mattered as much as intellect. He discusses rejection, the rise of anti-angiogenesis and polymer drug delivery, and how industry, philanthropy, and big ambitions enabled his lab to translate ideas into technologies for cancer, vaccines, insulin delivery, and global health.

Main Topics: Early life and intellectual formation (Priority: 4/5): Langer describes growing up in Albany in a normal, supportive middle-class family, where math games, toys like chemistry sets and erector sets, and early independence helped spark his interest in science and engineering. Education, career choices, and rejection (Priority: 5/5): He explains how he chose chemical engineering almost by elimination, disliked several technical paths, and faced repeated rejection from faculty jobs and grants before finding an opening through Judah Folkman. Anti-angiogenesis and polymer drug delivery breakthroughs (Priority: 5/5): Langer recounts how his engineering mindset helped solve a key technical problem in Folkman’s angiogenesis research: designing polymers that could deliver molecules slowly and biocompatibly, leading to landmark Nature and Science papers in 1976. MIT tenure, validation, and changing scientific norms (Priority: 4/5): He describes being initially marginalized at MIT, then gradually gaining credibility as his ideas were used widely, cited heavily, and validated by industry adoption and academy elections. Translation, startups, and working with industry (Priority: 5/5): Langer explains why he became receptive to startups and consulting after seeing large companies fail to advance the technology, and how small companies like Nova Pharmaceuticals could move innovations toward the clinic. Impact-driven current research and global health (Priority: 5/5): He details ongoing projects with the Gates Foundation and others: long-acting pills, single-shot vaccines, micronutrient delivery, aerosols, contraception, and oral insulin, all aimed at improving compliance and scalability. Leadership, mentoring, and career philosophy (Priority: 4/5): Langer emphasizes giving trainees room to think, valuing good questions over good answers, and aiming for work that changes the world while training the next generation of scientists and entrepreneurs.

Key Arguments: High-impact science should prioritize problems that can materially change lives, not merely incremental technical gains. Stubbornness and persistence are essential to scientific success because real research involves repeated failure. An engineering approach—stepwise, practical, and problem-solving oriented—can unlock biomedical challenges that others miss. Early teaching and grant-writing experiences helped shape Langer’s later academic and entrepreneurial career. Small, focused companies are often better than large corporations at advancing risky platform technologies from lab to clinic. Philanthropy and NIH funding play complementary roles: NIH provides critical scientific scrutiny, while foundations can support mission-driven, high-impact work. The most important metric for a lab is impact on patients and populations, especially in global health. Good mentoring means helping students transition from answering questions to asking better ones.

Data Points: Age: 70 - Langer had recently turned 70 at the time of the conversation. Lab size: 100 people - He said he still runs a lab of about 100 people. Scientific companies founded: More than 20 - The introduction notes he has helped found over 20 biotech companies. Citation ranking: Most cited engineer in history; 6th most cited scientist ever - Introductory host remarks cite Google Scholar metrics. National academies: 3 - He is among a small number elected to the National Academy of Medicine, National Academy of Sciences, and National Academy of Engineering. Birthday symposium attendance: 600–700 people - Langer notes the size of his 70th birthday symposium audience. Albany birth year: 1948 - He states he was born in 1948. High school graduation year: 1966 - He graduated high school in 1966. Cornell graduation: 1970 - He completed undergraduate study at Cornell in 1970. MIT postdoc start: 1974 - He says he did the postdoc in 1974. MIT faculty start: 1977 - He joined MIT in 1977. MIT tenure: 1982 - He received tenure in 1982. First National Academy election: 1989 - He was elected to the National Academy of Medicine in 1989. Additional academy elections: 1992 - He was elected to the National Academy of Sciences and National Academy of Engineering in 1992. Initial grants rejected: First 9 - He says his first nine grants were rejected. Nature paper year: 1976 - Paper showing biocompatible polymers could release molecules of any size or charge. Science paper year: 1976 - Paper on diffusible angiogenesis inhibitors stopping blood vessels in rabbit eye. Family deaths avoided/compliance issue: 100,000 deaths; $300 billion - He cites a New York Times figure on heart disease deaths and healthcare costs due to nonadherence in the U.S. Developing-world compliance burden: Worse than U.S. - He says patient compliance problems are even more severe in low-resource settings. Vaccine delivery paper timeframe: About 1.5 years prior - He references a Science paper on printing vaccine particles for timed release. Potential dosing intervals: Week, month, year - He describes long-acting pills and vaccine systems designed to last various time periods. Insulin pill performance: Worked on pigs - The oral insulin device achieved comparable results to injection in pig studies. Scholar/alumni network: Hundreds of professors; many hundreds in companies - He says many alumni became professors or company employees/founders.

Pivotal Quotes: "Dream big dreams, dreams that you feel can change the world and make it a better place." — Bob Langer: His advice to younger scientists and entrepreneurs at the end of the interview. "In life, what's really important isn't just your ability to give good answers. You're really judged ultimately, I think, on the quality of questions you ask." — Bob Langer: He explains his mentoring philosophy and how he trains students and postdocs. "I was looking for something important, whereas if I went to the oil companies, I wasn't looking for something important." — Bob Langer: He contrasts his research ambitions with the incremental focus of many early industry jobs.

Implications: The interview shows how biomedical innovation often depends on persistence, interdisciplinary thinking, and translation pathways beyond large pharma. For listeners, it underscores that high-impact biotech can emerge from stubborn curiosity, mission-driven funding, and teams willing to tackle hard delivery problems.